Brian Stuglik served as the CEO of Verastem, Inc., a pharmaceutical company specializing in oncology, from July 2019 until his retirement in July 2023. He has over thirty years of experience in the pharmaceutical industry, primarily focusing on drug development...
Brian Stuglik served as the CEO of Verastem, Inc., a pharmaceutical company specializing in oncology, from July 2019 until his retirement in July 2023. He has over thirty years of experience in the pharmaceutical industry, primarily focusing on drug development and commercialization. Before joining Verastem, he held senior positions at Eli Lilly and Company, where he excelled in roles like Global Vice President for Oncology Marketing. He also started his own consultancy, Proventus Health Solutions, which helps biotech firms navigate complex drug development processes. Stuglik's education includes a Bachelor of Pharmacy from Purdue University. He was recognized for his contributions to Verastem's success with a substantial cash bonus upon retirement, a testament to his impact on the company's initiatives. During his time at Verastem, he participated actively in the Board of Directors and remained involved even after stepping down as CEO, illustrating his commitment to the company's future. His experience and leadership have positioned Verastem as a notable player in the oncology sector.